Last reviewed · How we verify

NCT04273009

Optimising Treatments for Faecal Incontinence

Completed NA Last updated 17 February 2020
What this trial tests

NA trial testing Renew VS PTNS in Faecal Incontinence in 50 participants. Completed in 11 September 2018.

Timeline
15 December 2016
Primary endpoint
11 August 2018
11 September 2018

Quick facts

Lead sponsorLondon North West Healthcare NHS Trust
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment50
Start date15 December 2016
Primary completion11 August 2018
Estimated completion11 September 2018

Drugs / interventions tested

Conditions studied

Sponsor

London North West Healthcare NHS Trust — full company profile →

Who can join

18 and older, any sex, with Faecal Incontinence or Pelvic Floor Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to directly compare two medical treatments for faecal incontinence: Renew™ Anal Insert and Percutaneous Tibial Nerve Stimulation (PTNS) for a period of 12 weeks. Both are routinely used in our practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Randomized Pilot Study: Anal Inserts Versus Percutaneous Tibial Nerve Stimulation in Patients With Fecal Incontinence.
    Leo CA, Thomas GP, Hodgkinson JD, Leeuwenburgh M, et al · · 2021 · cited 6× · PMID 33399411 · DOI 10.1097/dcr.0000000000001913

Verify or expand the search:

Other recruiting trials for Faecal Incontinence

Currently open trials in the same condition.

Other London North West Healthcare NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04273009.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing